1
|
Moreau J, Hammoudi N, Marthey L, Trang-Poisson C, Nachury M, Altwegg R, Grimaud JC, Orempuller S, Hébuterne X, Aubourg A, Baudry C, Seksik P, Roblin X, Nahon S, Savoye G, Mesnard B, Stefanescu C, Simon M, Coffin B, Fumery M, Carbonnel F, Peyrin-Biroulet L, Desseaux K, Allez M. Impact of an Education Programme on IBD Patients' Skills: Results of a Randomised Controlled Multicentre Study [ECIPE]. J Crohns Colitis 2021; 15:432-440. [PMID: 32969469 DOI: 10.1093/ecco-jcc/jjaa195] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Better patient knowledge on inflammatory bowel disease [IBD] could improve outcome and quality of life. The aim of this study was to assess if an education programme improves IBD patients' skills as regards their disease. METHODS The GETAID group conducted a prospective multicentre randomised controlled study. IBD patients were included at diagnosis, or after a significant event in the disease course. Patients were randomised between 'educated' or control groups for 6 months. Education was performed by trained health care professionals. A psycho-pedagogic score [ECIPE] was evaluated by a 'blinded' physician at baseline and after 6 and 12 months [M6 and M12]. The primary endpoint was the increase of ECIPE score at M6 of more than 20%. RESULTS A total of 263 patients were included in 19 centres (male:40%; median age:30.8; Crohn's disease [CD]:73%). Of these, 133 patients were randomised into the educated group and 130 into the control group. The median relative increase in ECIPE score at M6 was higher in the educated group as compared with the control group (16.7% [0-42.1%] vs 7% [0-18.8%], respectively, p = 0.0008). The primary endpoint was met in 46% vs 24% of the patients in the educated and control groups, respectively [p = 0.0003]. A total of 92 patients met the primary endpoint. In multivariate analysis, predictors of an increase of at least 20% of the ECIPE score were randomisation in the educated group (odds ratio [OR] = 2.59) and no previous surgery [OR = 1.92]. CONCLUSIONS These findings support the set-up of education programmes in centres involved in the management of IBD patients.
Collapse
Affiliation(s)
- J Moreau
- Gastroenterology Department, Hôpital Rangueil, Toulouse, France
| | - N Hammoudi
- Gastroenterology Department, APHP, Hôpital Saint-Louis, INSERM UMRS 1160, Université Paris Diderot, Sorbonne Paris-Cité University, Paris, France
| | - L Marthey
- Gastroenterology Department, Hôpital du Kremlin-Bicetre, Kremlin Bicetre, France
| | | | - M Nachury
- CHU Lille, Maladies de l'appareil digestif, Lille, France
| | - R Altwegg
- Gastroenterology Department, Hôpital St-Eloi, Montpellier, France
| | - J C Grimaud
- Gastroenterology Department, Hôpital Nord, Marseille, France
| | - S Orempuller
- Gastroenterology Department, Hôpital Rangueil, Toulouse, France
| | - X Hébuterne
- Gastroenterology Department, Hôpital Archet, Nice, France
| | - A Aubourg
- Gastroenterology Department, Hôpital Trousseau, Tours, France
| | - C Baudry
- Gastroenterology Department, APHP, Hôpital Saint-Louis, INSERM UMRS 1160, Université Paris Diderot, Sorbonne Paris-Cité University, Paris, France
| | - P Seksik
- Department of Gastroenterology, Centre de recherche Saint-Antoine, Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France
| | - X Roblin
- Gastroenterology Department, Hôpital de St-Etienne, St-Etienne, France
| | - S Nahon
- Gastroenterology Department, Hôpital de Montfermeil, Montfermeil, France
| | - G Savoye
- Gastroenterology Department, Hôpital Charles Nicolle, Rouen, France
| | - B Mesnard
- Gastroenterology Department, Hôpital Dron, Tourcoing, France
| | - C Stefanescu
- Gastroenterology Department, Hôpital Beaujon, Clichy, France
| | - M Simon
- Gastroenterology Department, Institut Mutualiste Monsouris, Paris, France
| | - B Coffin
- Gastroenterology Department, Hôpital Louis Mourier, Colombes, France
| | - M Fumery
- Gastroenterology Department, Hôpital Nord, Amiens, France
| | - F Carbonnel
- Gastroenterology Department, Hôpital du Kremlin-Bicetre, Kremlin Bicetre, France
| | - L Peyrin-Biroulet
- Department of Gastroenterology, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France
| | - K Desseaux
- SBIM, Hôpital Saint-Louis, Paris, France
| | - M Allez
- Gastroenterology Department, APHP, Hôpital Saint-Louis, INSERM UMRS 1160, Université Paris Diderot, Sorbonne Paris-Cité University, Paris, France
| | | |
Collapse
|
2
|
Georger F, Dos Santos E, Gazagne L, Berdagué P, Saib A, Nahon S, Piquet J, Amara W. [COV IMPACT: Stress exposure analysis among hospital staff in 2 hospitals in France during the COVID-19 pandemic]. Ann Cardiol Angeiol (Paris) 2020; 69:227-232. [PMID: 33059875 PMCID: PMC7510417 DOI: 10.1016/j.ancard.2020.09.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Accepted: 09/03/2020] [Indexed: 04/11/2023]
Abstract
The COVID-19 pandemic has swept through our hospitals which have had to adapt as a matter of urgency. We are aware that a health crisis of this magnitude is likely to generate mental disorders particularly affecting exposed healthcare workers. Being so brutal and global, this one-of the kind pandemic has been impacting the staff in their professional sphere but also within their private circle. The COV IMPACT study is an early assessment survey conducted for 2 weeks in May 2020, of the perception by all hospital workers of the changes induced in their professional activity by the pandemic. The study was carried out by a survey sent to the hospital staff of Béziers and Montfermeil. The readjusted working conditions were source of increased physical fatigue for 62 % of the respondents. Moral exhaustion was reported by 36 %. It was related to the stress of contracting the infection (72 %) but above all of transmitting it to relatives (89 %) with a broad perception of a vital risk (41 %). This stress affected all socio-professional categories (CSP) and was independent of exposure to COVID. Change in organisation, lack of information and protective gear and equipment were major factors of insecurity at the start of the epidemic. Work on supportive measures is necessary. It should focus on the spread of information, particularly towards the youngest, as well as bringing more psychological support and a larger amount of medical equipment, beyond healthcare workers and the COVID sectors.
Collapse
Affiliation(s)
- F Georger
- Centre hospitalier Béziers, 2, rue Valentin-Haüy, 34500 Béziers, France.
| | - E Dos Santos
- Centre hospitalier Béziers, 2, rue Valentin-Haüy, 34500 Béziers, France
| | - L Gazagne
- Centre hospitalier Béziers, 2, rue Valentin-Haüy, 34500 Béziers, France
| | - P Berdagué
- Centre hospitalier Béziers, 2, rue Valentin-Haüy, 34500 Béziers, France
| | - A Saib
- GHI Le Raincy-Montfermeil, 10, rue du General Leclerc, 93370 Montfermeil
| | - S Nahon
- GHI Le Raincy-Montfermeil, 10, rue du General Leclerc, 93370 Montfermeil
| | - J Piquet
- GHI Le Raincy-Montfermeil, 10, rue du General Leclerc, 93370 Montfermeil
| | - W Amara
- GHI Le Raincy-Montfermeil, 10, rue du General Leclerc, 93370 Montfermeil
| |
Collapse
|
3
|
Toumi E, Peyrade F, Nahon S, Marin L, Baillif S, Martel A. [Orbital mantle cell lymphoma succesfully treated by Bcl-2 inhibitor: Report of a case]. J Fr Ophtalmol 2020; 44:239-243. [PMID: 32981740 DOI: 10.1016/j.jfo.2020.02.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 02/17/2020] [Accepted: 02/25/2020] [Indexed: 10/23/2022]
Abstract
Lymphoma is the most common orbital malignancy in adults. Among the types of lymphoma, mantle cell lymphoma is a particularly aggressive form, often discovered through systemic involvement, with a dismal prognosis due to frequent recurrences. It is secondary to a t (11 ; 14) (q13; q32) chromosomal translocation resulting in an anti-apoptotic signal via overexpression of Bcl-2. Treatment is based on R-CHOP poly-chemotherapy. We describe the case of a patient with an orbital recurrence of mantle cell lymphoma successfully treated with oral Bcl-2 inhibitor monotherapy. A 58-year-old man who was treated with R-CHOP 8 years ago for mantle cell lymphoma, in remission for 5 years, presented with progressive decreased visual acuity in the left eye, along with binocular diplopia. Clinical examination revealed a decrease in visual acuity in the left eye to 1/20 Parinaud 20 and a relative afferent pupillary defect on the left. External examination revealed a left cranial nerve VI palsy, 2mm of painless proptosis, and hypesthesia of the left V1 territory, leading to a diagnosis of left orbital apex syndrome. The disc and macular OCT were normal. The visual field showed enlargement of the left blind spot. An emergency CT scan and MRI revealed an apical extraconal tissue mass infiltrating the medial rectus muscle, extending to the superior orbital fissure, optic canal and left cavernous sinus, hyperintense on T2 weighted images and isointense on T1. The morphological appearance was strongly suggestive of an infiltrative lymphomatous process. An 18 FDG PET-scan identified the orbital lesion as well as enhancing lesions in the axilla and colon; given the clinical features and test results, the diagnosis of recurrent mantle cell lymphoma was made without biopsy. Treatment with Venetoclax (Bcl-2 inhibitor) was initiated. At one month of treatment, the orbital apex syndrome had entirely resolved, with visual acuity increased to 8/10 Parinaud 4 and a metabolic return to normal on PET scan. The PET scanner and clinical examination at 3 months were entirely normal. At the one-year follow-up visit, the patient was still on Venetoclax, the clinical examination was unchanged, and the PET-scan still showed a complete metabolic response.
Collapse
Affiliation(s)
- E Toumi
- CHU Pasteur II, service d'ophtalmologie, 30, voie Romaine, 06000 Nice, France.
| | - F Peyrade
- Service d'oncologie, centre Antoine Lacassagne, 33 avenue de Valombrose, 06189 Nice Cedex 2, France
| | - S Nahon
- CHU Pasteur II, service d'ophtalmologie, 30, voie Romaine, 06000 Nice, France
| | - L Marin
- CHU Pasteur II, service d'ophtalmologie, 30, voie Romaine, 06000 Nice, France
| | - S Baillif
- CHU Pasteur II, service d'ophtalmologie, 30, voie Romaine, 06000 Nice, France
| | - A Martel
- CHU Pasteur II, service d'ophtalmologie, 30, voie Romaine, 06000 Nice, France
| |
Collapse
|
4
|
Martini K, Fevrier E, Nahon S, Baillif S, Martel A. Bilateral swinging Ozurdex in a patient with bilateral anterior uveitis after cataract surgery. J Fr Ophtalmol 2020; 43:944-946. [PMID: 32807549 DOI: 10.1016/j.jfo.2019.12.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2019] [Accepted: 12/05/2019] [Indexed: 11/19/2022]
Affiliation(s)
- K Martini
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, voie Romaine, 06000 Nice, France
| | - E Fevrier
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, voie Romaine, 06000 Nice, France
| | - S Nahon
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, voie Romaine, 06000 Nice, France
| | - S Baillif
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, voie Romaine, 06000 Nice, France; Université Cote d'Azur, Nice, France
| | - A Martel
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, voie Romaine, 06000 Nice, France; Université Cote d'Azur, Nice, France; Centre méditerranéen de médecine moléculaire (C3M), Equipe 1, Nice, France.
| |
Collapse
|
5
|
Gbeto CC, Quaranta S, Mari R, Fanciullino R, Roche C, Nahon S, Solas C, Ouafik L, Lacarelle B, Allegre T, Ciccolini J. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. Pharmacogenomics 2020; 20:931-938. [PMID: 31486738 DOI: 10.2217/pgs-2019-0028] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Dihydropryimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with severe or lethal toxicities with oral capecitabine. Usually, patients with history of 5-FU-based therapy with no signs for life-threatening toxicities are considered as not DPD-deficient individuals who can be safely treated next with capecitabine if required. Here we describe the case of a woman originally treated with standard FEC100 protocol for metastatic breast cancer with little severe toxicities but grade-3 mucosities that were quickly resolved by symptomatic treatment. When switched to capecitabine + vinorelbine combo, extremely severe toxicities with fatal outcome were unexpectedly observed. Pharmacogenetic investigations were performed on cytidine deaminase and DPYD, and showed that this patient was heterozygous for the 2846A>T mutation on the DPYD gene. DPD phenotyping (i.e., uracil plasma levels >250 ng/ml, dihydrouracil/uracil ratio <0.5) confirmed that this patient was profoundly DPD deficient. Differences in fluoropyrimidine dosing between FEC100 (i.e., 500 mg/m2 5-FU) and capecitabine (i.e., 2250 mg daily) could explain why initial 5-FU-based protocol did not lead to life-threatening toxicities, whereas capecitabine rapidly triggered toxic death. Overall, this case report suggests that any toxicity, even when not life threatening, should be considered as a warning signal for possible underlying profound DPD deficiency syndrome, especially with low-dose protocols.
Collapse
Affiliation(s)
- Crescent C Gbeto
- Department of Hematology Oncology & Internal Médicine Centre Hospitalier d'Aix en Provence, Aix-en-Provence, France
| | | | - Roxane Mari
- Department of Hematology Oncology & Internal Médicine Centre Hospitalier d'Aix en Provence, Aix-en-Provence, France
| | - Raphaelle Fanciullino
- SMARTc Unit, Pharmacokinetics Laboratory, CRCM UMR Inserm 1068, Aix Marseille Univ Marseille, France
| | | | - Sophie Nahon
- Department of Hematology Oncology & Internal Médicine Centre Hospitalier d'Aix en Provence, Aix-en-Provence, France
| | - Caroline Solas
- Medical Biology Department, APHM Marseille, France.,SMARTc Unit, Pharmacokinetics Laboratory, CRCM UMR Inserm 1068, Aix Marseille Univ Marseille, France
| | | | - Bruno Lacarelle
- Medical Biology Department, APHM Marseille, France.,SMARTc Unit, Pharmacokinetics Laboratory, CRCM UMR Inserm 1068, Aix Marseille Univ Marseille, France
| | - Thierry Allegre
- Department of Hematology Oncology & Internal Médicine Centre Hospitalier d'Aix en Provence, Aix-en-Provence, France
| | - Joseph Ciccolini
- Medical Biology Department, APHM Marseille, France.,SMARTc Unit, Pharmacokinetics Laboratory, CRCM UMR Inserm 1068, Aix Marseille Univ Marseille, France
| |
Collapse
|
6
|
Retornaz F, Guillem O, Rousseau F, Morvan F, Rinaldi Y, Nahon S, Castagna C, Boulahssass R, Grino M, Gholam D. Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study. Oncologist 2020; 25:e85-e93. [PMID: 31387952 PMCID: PMC6964155 DOI: 10.1634/theoncologist.2019-0241] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 07/08/2019] [Indexed: 12/15/2022] Open
Abstract
PURPOSE Older patients with colon cancer (CC) are vulnerable to chemotherapy toxicity and death. Establishing simple scores specific for patients with CC to predict severe chemotoxicity or early death is needed to select the best treatment strategy. SUBJECTS, MATERIALS, AND METHODS This prospective multicenter study included patients aged ≥70 years with CC receiving adjuvant or first-line metastatic chemotherapy. Frailty markers (nutrition, physical activity, energy, mobility, strength), comprehensive geriatric assessment (functional status, comorbidities, falls, nutrition, cognition, and depression), and usual laboratory parameters were collected. Logistic or Cox regression was used to examine at 500 days the association between frailty markers, comprehensive geriatric assessment, laboratory parameters, and grade 3-4 toxicity or death. RESULTS A total of 97 patients (median age, 79.0 years) received adjuvant (37.1%) or metastatic (62.9%) chemotherapy. During the first 500 days, grade 3-4 toxicity occurred in 49.5%, and 30% died. The predictive model for grade 3-4 toxicity combined (polychemotherapy × 3) + (hypoalbuminemia <32 g/L × 2) + (abnormal grip strength × 1.5) + C-reactive protein >11 mg/L + Eastern Cooperative Oncology Group performance status (ECOG-PS), cutoff score >3. The predictive model for death combined (metastasis × 5) + (age × 2) + alkaline phosphatase >100 IU/mL + sex (female) + abnormal grip strength + ECOG-PS, cutoff score >6. For chemotoxicity prediction, sensitivity was 81.6% and specificity 71.4%. For death prediction, sensitivity was 89.7% and specificity was 83.6%. CONCLUSION These simple and efficient "ColonPrediscores" will help to better identify older patients with CC with increased risk of chemotherapy-related toxicity and/or death. IMPLICATIONS FOR PRACTICE The two scores assessed in this study, called "ColonPrediscores", offer a major advantage in that they do not need a previous complete geriatric assessment, which makes them an easy-to-use tool in oncologic settings.
Collapse
Affiliation(s)
- Frédérique Retornaz
- Internal Medicine Research and Care Unit, European HospitalMarseilleFrance
- Geriatric Day Hospital Unit, State Geriatric CenterMarseilleFrance
| | - Olivier Guillem
- Geriatric Medicine Unit, Inter‐communal Hospital Center from Southern AlpsGapFrance
| | - Frédérique Rousseau
- Geriatric Coordination Unit for Geriatric Oncology PACA Ouest, Paoli Calmettes InstituteMarseilleFrance
| | | | | | - Sophie Nahon
- Hematology/Oncology Day Hospital, Hospital Center du Pays d'AixAix en ProvenceFrance
| | - Chantal Castagna
- Geriatric Mobile Unit, Hospital Center Toulon La SeyneToulonFrance
| | - Rabia Boulahssass
- Geriatric Coordination Unit for Geriatric Oncology PACA Est FHU ONCOAGE, Hospital University CenterNiceFrance
| | - Michel Grino
- Department of Clinical Research, State Geriatric CenterMarseilleFrance
- Aix‐Marseille University, INSERM, INRA, C2VNMarseilleFrance
| | - Dany Gholam
- Hemato‐Oncology Unit, Saint George Hospital University Medical Center SGHUMC, BeirutLebanon
| |
Collapse
|
7
|
Martel A, Fevrier E, Nahon S, Grosse JP, Baillif S. [Surgical removal of a huge intra orbital wood foreign body]. J Fr Ophtalmol 2019; 42:531-533. [PMID: 30979556 DOI: 10.1016/j.jfo.2018.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 12/07/2018] [Indexed: 10/27/2022]
Affiliation(s)
- A Martel
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 06100 Nice, France.
| | - E Fevrier
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 06100 Nice, France
| | - S Nahon
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 06100 Nice, France
| | - J P Grosse
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 06100 Nice, France
| | - S Baillif
- Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 06100 Nice, France
| |
Collapse
|
8
|
Couderc AL, Nouguerède E, Baumstarck K, Loubière S, Le Caer H, Guillem O, Rousseau F, Greillier L, Norguet-Monnereau E, Cecile M, Boulahssass R, Le Caer F, Tournier S, Butaud C, Guillet P, Nahon S, Kirscher S, Diaz N, Morando C, Villani P, Auquier P, Daumas A. PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: update to the study protocol for a randomized controlled trial. Trials 2019; 20:54. [PMID: 30646923 PMCID: PMC6334455 DOI: 10.1186/s13063-018-3127-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Accepted: 12/11/2018] [Indexed: 11/10/2022] Open
Abstract
Background Social isolation potentiates the risk of death by cancer in the older cancer patient population. The PREDOMOS study investigates the impact of establishing a Program of Social intervention associated with techniques of Domotic and Remote assistance on the improvement of quality of life of older isolated patients, treated for locally advanced or metastatic cancer. This paper updates the pilot trial protocol. Methods/design The original protocol was published in Trials, accessible at https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-1894-7. This update reports on the eligibility criteria expansion and on the adjunction of a cost-utility analysis. We widened the eligible population to patients with locally advanced or metastatic cancer including malignant hemopathies (except acute myeloid leukemia) and to patients in the first and second lines of oncologic treatment. We restricted the inclusion to patients with a Mini Mental State Examination score strictly over 24. In addition to the secondary outcomes outlined in the protocol, a medico-economic analysis has been added to evaluate both the health benefits and costs of the two strategies and calculate the incremental cost-utility ratio of the innovative program assessed, compared to the standard practice. Trial registration ClinicalTrials.gov, NCT02829762. Registered on 29 June 2016.
Collapse
Affiliation(s)
- Anne-Laure Couderc
- Service de Médecine Interne Gériatrie et Thérapeutique, CHU Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France.,Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France
| | - Emilie Nouguerède
- Service de Médecine Interne Gériatrie et Thérapeutique, CHU Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France. .,Service d'Oncologie Digestive, CHU Timone, AP-HM, 264 Rue Saint Pierre, 13385, Marseille, cedex 05, France.
| | - Karine Baumstarck
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, cedex 05, France
| | - Sandrine Loubière
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, cedex 05, France
| | - Hervé Le Caer
- Service de Pneumologie, CH Yves le Foll, 10 rue Marcel Proust, Saint-Brieuc, France
| | - Olivier Guillem
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Onco-Gériatrie, CH Intercommunal des Alpes du Sud Site de Gap (CHICAS), 1 Place Auguste Muret, 05000, Gap, France
| | - Frédérique Rousseau
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Oncologie Médicale, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite Dromel, 13009, Marseille, France
| | - Laurent Greillier
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Oncologie Multidisciplinaire et Innovation Thérapeutique, CHU NORD, AP-HM, Chemin des Bourrely, 13915, Marseille, cedex 20, France
| | - Emmanuelle Norguet-Monnereau
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Oncologie Digestive, CHU Timone, AP-HM, 264 Rue Saint Pierre, 13385, Marseille, cedex 05, France
| | - Maud Cecile
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Oncologie Médicale, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite Dromel, 13009, Marseille, France
| | - Rabia Boulahssass
- Service de Gérontologie, Hôpital de Cimiez, 4 Avenue Reine Victoria, CS 91179, 06003, Nice, France
| | - Françoise Le Caer
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service de Gériatrie, CH Yves le Foll, 10 rue Marcel Proust, Saint-Brieuc, France
| | - Sandrine Tournier
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service de Gériatrie, Hôpital Saint Joseph, 26 Boulevard Louvain, 13285, Marseille, cedex 08, France
| | - Chantal Butaud
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Unité Mobile de Gériatrie, Hôpital Saint Musse, CH Intercommunal Toulon-La Seyne sur Mer (CHITS), 54 Rue Henri Claire Deville, 83000, Toulon, France
| | - Pierre Guillet
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Unité Mobile de Gériatrie, Hôpital Saint Musse, CH Intercommunal Toulon-La Seyne sur Mer (CHITS), 54 Rue Henri Claire Deville, 83000, Toulon, France
| | - Sophie Nahon
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Hémato-Oncologie, CH du Pays d'Aix, Avenue les Tamaris, 13616, Aix-en-Provence, France
| | - Sylvie Kirscher
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, France.,Service d'Oncologie Médicale, Institut Sainte Catherine (ISC), 250 Chemin de Baigne Pieds, 84918, Avignon, cedex 09, France
| | - Nadine Diaz
- Service Social, Hôpital Sainte Marguerite, AP-HM, 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France
| | - Claire Morando
- Direction de la Recherche Clinique et de l'Innovation (DRCI), AP-HM, 80 Rue Brochier, 13354, Marseille, cedex 05, France
| | - Patrick Villani
- Service de Médecine Interne Gériatrie et Thérapeutique, CHU Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France
| | - Pascal Auquier
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille, cedex 05, France
| | - Aurélie Daumas
- Service de Médecine Interne Gériatrie et Thérapeutique, CHU Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille, cedex 09, France
| |
Collapse
|
9
|
Martinez S, Leflem C, Nahon S, Roche S, Tadrist Z, Bernardi M. Programme d’éducation thérapeutique en cancérologie (SMILE). Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF, Adenis A, Alessio A, Aouakli A, Azzedine A, Bedjaoui A, Bidault A, Blanchi A, Botton A, Cadier-Lagnes A, Fatisse A, Gagnaire A, Gilbert A, Gueye A, Hollebecque A, Lemaire A, Mahamat A, Marre A, Patenotte A, Rotenberg A, Roussel A, Thirot-Bidault A, Votte A, Weber A, Zaanan A, Dupont-Gossart A, Villing A, Queuniet A, Coudert B, Denis B, Garcia B, Lafforgue B, Landi B, Leduc B, Linot B, Paillot B, Rhein B, Winkfield B, Barberis C, Becht C, Belletier C, Berger C, Bineau C, Borel C, Brezault C, Buffet C, Cornila C, Couffon C, De La Fouchardière C, Giraud C, Lecaille C, Lepere C, Lobry C, Locher C, Lombard-Bohas C, Paoletti C, Platini C, Rebischung C, Sarda C, Vilain C, Briac-Levaché C, Auby D, Baudet-Klepping D, Bechade D, Besson D, Cleau D, Festin D, Gargot D, Genet D, Goldfain D, Luet D, Malka D, Peré-Vergé D, Pillon D, Sevin-Robiche D, Smith D, Soubrane D, Tougeron D, Zylberait D, Carola E, Cuillerier E, Dorval Danquechin E, Echinard E, Janssen E, Maillard E, Mitry E, Norguet-Monnereau E, Suc E, Terrebonne E, Zrihen E, Pariente E, Almaric F, Audemar F, Bonnetain F, Desseigne F, Dewaele F, Di Fiore F, Ghiringhelli F, Husseini F, Khemissa F, Kikolski F, Morvan F, Petit-Laurent F, Riot F, Subtil F, Zerouala-Boussaha F, Caroli-Bosc F, Boilleau-Jolimoy G, Bordes G, Cavaglione G, Coulanjon G, Deplanque G, Gatineau-Saillant G, Goujon G, Medinger G, Roquin G, Brixi-Benmansour H, Castanie H, Lacroix H, Maechel H, Perrier H, Salloum H, Senellart H, Baumgaertner I, Cumin I, Graber I, Trouilloud I, Boutin J, Butel J, Charneau J, Cretin J, Dauba J, Deguiral J, Egreteau J, Ezenfis J, Forestier J, Goineau J, Lacourt J, Lafon J, Martin J, Meunier J, Moreau J, Provencal J, Taieb J, Thaury J, Tuaillon J, Vergniol J, Villand J, Vincent J, Volet J, Bachet J, Barbare J, Souquet J, Grangé J, Dor J, Paitel J, Jouve J, Raoul J, Cheula J, Gornet J, Sabate J, Vantelon J, Vaillant J, Aucouturier J, Barbieux J, Herr J, Lafargue J, Lagasse J, Latrive J, Plachot J, Ramain J, Robin J, Spano J, Douillard J, Beerblock K, Bouhier-Leporrier K, Slimane Fawzi K, Cany L, Chone L, Dahan L, Gasnault L, Rob L, Stefani L, Wander L, Baconnier M, Ben Abdelghani M, Benchalal M, Blasquez M, Carreiro M, Charbit M, Combe M, Duluc M, Fayolle M, Gignoux M, Giovannini M, Glikmanas M, Mabro M, Mignot M, Mornet M, Mousseau M, Mozer M, Pauwels M, Pelletier M, Porneuf M, Ramdani M, Schnee M, Tissot M, Zawadi M, Clavero-Fabri M, Gouttebel M, Kaminsky M, Galais M, Abdelli N, Barrière N, Bouaria N, Bouarioua N, Delas N, Gérardin N, Hess-Laurens N, Stremsdoerfer N, Berthelet O, Boulat O, Capitain O, Favre O, Amoyal P, Bergerault P, Burtin P, Cassan P, Chatrenet P, Chiappa P, Claudé P, Couzigou P, Feydy P, Follana P, Geoffroy P, Godeau P, Hammel P, Laplaige P, Lehair P, Martin P, Novello P, Pantioni P, Pienkowski P, Pouderoux P, Prost P, Ruszniewski P, Souillac P, Texereau P, Thévenet P, Haineaux P, Benoit R, Coriat R, Lamy R, Mackiewicz R, Beorchia S, Chaussade S, Hiret S, Jacquot S, Lavau Denes S, Montembault S, Nahon S, Nasca S, Nguyen S, Oddou-Lagraniere S, Pesque-Penaud S, Fratte S, Chatellier T, Mansourbakht T, Morin T, Walter T, Boige V, Bourgeois V, Derias V, Guérin-Meyer V, Hautefeuille V, Jestin Le Tallec V, Lorgis V, Quentin V, Sebbagh V, Veuillez V, Adhoute X, Coulaud X, Becouarn Y, Coscas Y, Courouble Y, Le Bricquir Y, Molin Y, Rinaldi Y, Lam Y, Ladhib Z. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. Eur J Cancer 2018; 98:1-9. [DOI: 10.1016/j.ejca.2018.03.031] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2018] [Revised: 03/26/2018] [Accepted: 03/28/2018] [Indexed: 02/07/2023]
|
11
|
Nahon S. Prise en charge des patients ayant une maladie inflammatoire chronique de l’intestin hospitalisés en médecine intensive et réanimation. Méd Intensive Réa 2018. [DOI: 10.3166/rea-2018-0045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Les patients ayant une maladie inflammatoire chronique de l’intestin (MICI) [maladie de Crohn ou rectocolite hémorragique] ont une probabilité plus importante d’être hospitalisés en médecine intensive et réanimation (MIR) soit en raison de leur traitement immunosuppresseur et/ou biothérapie (parfois associés) qui est à l’origine d’un surrisque d’infections notamment respiratoires soit en raison d’un risque accru de thromboses veineuses profondes ou artérielles. Ces complications directement ou non liées à la MICI sont associées à une morbidité et à une mortalité accrues. Certaines de ces complications peuvent être prévenues notamment par une vaccination adaptée des patients traités par immunosuppresseurs et par la prescription systématique d’une héparine de bas poids moléculaire chez tout patient ayant une MICI en poussée et/ou hospitalisé quelle qu’en soit la raison.
Collapse
|
12
|
Retornaz F, Guillem O, Gholam D, Codoul JF, Brativesic C, Morvan F, Rinaldi Y, Barriere N, Nahon S, Butaud C, Guerin O, Boulahssass R, Grino M, Rousseau F. Predicting chemotherapy toxicity and death in older adults with colon cancer: Results of MOST (Massilia Oncologic Senior Tests) study. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.10041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Dany Gholam
- Centre Hospitalier de la Dracenie, Draguignan, France
| | | | | | | | | | | | - Sophie Nahon
- Centre Hospitalier d'Aix en Provence, Aix En Provence, France
| | | | - Olivier Guerin
- Department of Geriatric Medicine, Cimiez Hospital, FHU Oncoage, University Côte d’Azur, Nice, France
| | | | - Michel Grino
- Centre Gérontologique Départemental de Marseille, Marseille, France
| | | |
Collapse
|
13
|
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Fumery M, Carbonnel F, Bommelaer G, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Lambert J, Mary JY, Louis E. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018; 67:237-243. [PMID: 28053054 DOI: 10.1136/gutjnl-2016-313060] [Citation(s) in RCA: 96] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2016] [Revised: 12/09/2016] [Accepted: 12/11/2016] [Indexed: 12/14/2022]
Abstract
OBJECTIVE Ciclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess long-term outcome of patients included in a randomised trial comparing ciclosporin and infliximab. DESIGN Between 2007 and 2010, 115 patients with steroid-refractory ASUC were randomised in 29 European centres to receive ciclosporin or infliximab in association with azathioprine. Patients were followed until death or last news up to January 2015. Colectomy-free survival rates at 1 and 5 years and changes in therapy were estimated through Kaplan-Meier method and compared between initial treatment groups through log-rank test. RESULTS After a median follow-up of 5.4 years, colectomy-free survival rates (95% CI) at 1 and 5 years were, respectively, 70.9% (59.2% to 82.6%) and 61.5% (48.7% to 74.2%) in patients who received ciclosporin and 69.1% (56.9% to 81.3%) and 65.1% (52.4% to 77.8%) in those who received infliximab (p=0.97). Cumulative incidence of first infliximab use at 1 and 5 years in patients initially treated with ciclosporin was, respectively, 45.7% (32.6% to 57.9%) and 57.1% (43.0% to 69.0%). Only four patients from the infliximab group were subsequently switched to ciclosporin. Three patients died during the follow-up, none directly related to UC or its treatment. CONCLUSIONS In this cohort of patients with steroid-refractory ASUC initially treated by ciclosporin or infliximab, long-term colectomy-free survival was independent from initial treatment. These long-term results further confirm a similar efficacy and good safety profiles of both drugs and do not favour one drug over the other. TRIAL REGISTRATION NUMBER EudraCT: 2006-005299-42; ClinicalTrials.gouv number: NCT00542152; post-results.
Collapse
Affiliation(s)
- D Laharie
- CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive-Université de Bordeaux, Bordeaux, France
| | - A Bourreille
- CHU de Nantes, Hôtel-Dieu, Hépato-Gastroentérologie, Institut des Maladies de l'Appareil Digestif, Nantes, France
| | - J Branche
- CHRU de Lille, Hôpital Claude Huriez, Service des maladies de l'appareil digestif-Endoscopie digestive, Lille, France
| | - M Allez
- Hôpital Saint-Louis, service d'Hépato-Gastroentérologie, APHP-Université Paris VII, Paris, France
| | - Y Bouhnik
- Hôpital Beaujon, Gastroentérologie, MICI et Assistance Nutritive, APHP-Université Paris VII, Clichy, France
| | - J Filippi
- CHU de Nice, Hôpital de l'Archet 2, Service de Gastroentérologie et Nutrition Clinique, Nice, France
| | - F Zerbib
- CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive-Université de Bordeaux, Bordeaux, France
| | - G Savoye
- CHU de Rouen, Hôpital Charles Nicolle, service de Gastroentérologie, UMR 1073″, Normandie Université-Rouen, Rouen, France
| | - L Vuitton
- CHU de Besançon, Hôpital Jean Minjoz, Service de Gastroentérologie, Besançon, France
| | - J Moreau
- CHU de Toulouse, Hôpital Rangueil, Service de Gastro-entérologie et Nutrition, Toulouse, France
| | - A Amiot
- Hôpital Henri Mondor, Service d'Hépato-gastroentérologie, APHP-Université Créteil, Créteil, France
| | - J Cosnes
- Hôpital St-Antoine, service de Gastroentérologie, Paris, France
| | - E Ricart
- Gastroenterology Department, Hospital. Clinic, IDIBAPS, CIBEREHD, Barcelona, Spain
| | - O Dewit
- UCL Saint Luc, Service d'Hépato-Gastroentérologie, Brussels, Belgium
| | - A Lopez-Sanroman
- Hospital Ramon y Cajal, Unidad de EII/IBD Unit, Servicio de Gastroenterología y Hepatología, Madrid, Spain
| | - M Fumery
- CHU Amiens, Hôpital Nord, service d'Hépato-Gastroentérologie, Amiens, France
| | - F Carbonnel
- Hôpital Bicêtre, service d'Hépato-Gastroentérologie, APHP-Université Paris Sud 11,Le Kremlin Bicêtre, France
| | - G Bommelaer
- CHU Clermont-Ferrand, Service Hépatologie-Gastro-entérologie, Clermont-Ferrand, France
| | - B Coffin
- Hôpital Louis Mourier, service d'Hépato-Gastroentérologie, Pôle Maladie Appareil Digestif, APHP-Université Paris VII, Colombes, France
| | - X Roblin
- CHU de Saint-Etienne, Hôpital Nord, Service de Gastro-entérologie et Hépatologie, Saint-Etienne, France
| | - G van Assche
- Division of Gastroenterology, University Hospital of Leuven, Leuven, Belgium
| | - M Esteve
- Department of Gastroenterology, Hospital Universitari Mútua de Terrassa, University of Barcelona, Terrassa. CIBEREHD, Catalonia, Spain
| | - M Farkkila
- Helsinki University, and Helsinki University Central Hospital, Clinic of Gastroenterology, HUS, Finland
| | - J P Gisbert
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | - P Marteau
- Hôpital St-Antoine, service de Gastroentérologie, Paris, France
| | - S Nahon
- CHI Le Raincy Montfermeil, Service d'Hépato-gastroentérologie, Montfermeil, France
| | - M de Vos
- Ghent University Hospital, Gent, Belgium
| | - J Lambert
- UMR-S- 1153 Inserm, Equipe ECSTRA, Denis Diderot-Paris 7 University, Hôpital Saint-Louis, Paris, France
| | - J Y Mary
- UMR-S- 1153 Inserm, Equipe ECSTRA, Denis Diderot-Paris 7 University, Hôpital Saint-Louis, Paris, France
| | - E Louis
- Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium
| | | |
Collapse
|
14
|
Zamparini E, Ahmed P, Belhassan M, Horaist C, Bouguerba A, Ayed S, Barchasz J, Boukari M, Goldgran-Toledano D, Yaacoubi S, Bornstain C, Nahon S, Vincent F. Orientation des patients adultes consultant aux urgences pour hémorragie digestive (hors hypertension portale prouvée ou présumée) : intérêt des scores pronostiques. Méd Intensive Réa 2017. [DOI: 10.1007/s13546-017-1288-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
15
|
Crétel-Durand E, Nouguerède E, Le Caer H, Rousseau F, Retornaz F, Guillem O, Couderc AL, Greillier L, Norguet E, Cécile M, Boulahssass R, Le Caer F, Tournier S, Butaud C, Guillet P, Nahon S, Poudens L, Kirscher S, Loubière S, Diaz N, Dhorne J, Auquier P, Baumstarck K. PREDOMOS study, impact of a social intervention program for socially isolated elderly cancer patients: study protocol for a randomized controlled trial. Trials 2017; 18:174. [PMID: 28403911 PMCID: PMC5389099 DOI: 10.1186/s13063-017-1894-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Accepted: 03/10/2017] [Indexed: 12/27/2022] Open
Abstract
Background Cancer incidence and social isolation increase along with advanced age, and social isolation potentiates the relative risk of death by cancer. Once spotted, social isolation can be averted with the intervention of a multidisciplinary team. Techniques of automation and remote assistance have already demonstrated their positive impact on falls prevention and quality of life (QoL), though little is known about their impact on socially isolated elderly patients supported for cancer. The primary objective of the PREDOMOS study is to evaluate the impact of establishing a Program of Social intervention associated with techniques of Domotic and Remote assistance (PS-DR) on the improvement of QoL of elderly isolated patients, treated for locally advanced or metastatic cancer. The secondary objectives include treatment failure, tolerance, survival, and autonomy. Methods/design This trial is a multicenter, prospective, randomized, placebo-controlled, open-label, two-parallel group study. The setting is 10 French oncogeriatric centers. Inclusion criteria are patients aged at least 70 years with a social isolation risk and a histological diagnosis of cancer, locally advanced or metastatic disease. The groups are (1) the control group, receiving usual care; (2) the experimental group, receiving usual care associating with monthly social assistance, domotic, and remote assistance. Participants are randomized in a 1:1 allocation ratio. Evaluation times involve inclusion (randomization) and follow-up (12 months). The primary endpoint is QoL at 3 months (via European Organization for Research and Treatment of Cancer (EORTC) QLQ C30); secondary endpoints are social isolation, time to treatment failure, toxicity, dose response-intensity, survival, autonomy, and QoL at 6 months. For the sample size, 320 individuals are required to obtain 90% power to detect a 10-point difference (standard deviation 25) in QoL score between the two groups (20% loss to follow-up patients expected). Discussion The randomized controlled design is the most appropriate design to demonstrate the efficacy of a new experimental strategy (Evidence-Based Medicine Working Group classification). National and international recommendations could be updated based on the findings of this study. Trial registration ClinicalTrials.gov, NCT02829762. Registered on 29 June 2016. Electronic supplementary material The online version of this article (doi:10.1186/s13063-017-1894-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Elodie Crétel-Durand
- Unit of Transversal Onco-Geriatry (UTOG), Service de Médecine Interne et Gériatrie Thérapeutique, 264 Rue Saint Pierre, 13385, Marseille cedex 05, France.,Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France
| | - Emilie Nouguerède
- Unit of Transversal Onco-Geriatry (UTOG), Service de Médecine Interne et Gériatrie Thérapeutique, 264 Rue Saint Pierre, 13385, Marseille cedex 05, France. .,CRO2 UMR_S 911, INSERM, Aix-Marseille Université, 27 Boulevard Jean Moulin, 13385, Marseille cedex 05, France.
| | - Hervé Le Caer
- Service de Pneumologie, CH Saint Brieuc - Hôpital Ives Le Foll, 10 Rue Marcel Proust, 22000, Saint Brieuc, France
| | - Frédérique Rousseau
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service d'Oncologie Médicale, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite Dromel, 13009, Marseille, France
| | - Frédérique Retornaz
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Centre de Gérontologie Départemental, 176 Avenue de Montolivet, 13012, Marseille, France
| | - Olivier Guillem
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service d'Onco-Gériatrie, CH Intercommunal des Alpes du Sud Site de Gap (CHICAS), 1 Place Auguste Muret, 05000, Gap, France
| | - Anne-Laure Couderc
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service de Médecine Interne et Gériatrie Thérapeutique, Hôpital Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille cedex 09, France
| | - Laurent Greillier
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Oncologie Multidisciplinaire et Innovation Thérapeutique, CHU NORD, Assistance Publique des Hôpitaux de Marseille (AP-HM), Chemin des Bourrely, 13915, Marseille cedex 20, France
| | - Emmanuelle Norguet
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service d'Oncologie Digestive, CHU Timone, Assistance Publique des Hôpitaux de Marseille (AP-HM), 264 Rue Saint Pierre, 13385, Marseille cedex 05, France
| | - Maud Cécile
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service d'Oncologie Médicale, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite Dromel, 13009, Marseille, France
| | - Rabia Boulahssass
- Service de Gérontologie, Hôpital de Cimiez, 4 Avenue Reine Victoria, CS 91179, 06003, Nice, France
| | - Francoise Le Caer
- Pôle de Gériatrie, CH Saint Brieuc, Hôpital Yves Le Foll, 10 Rue Marcel Proust, 22000, Saint Brieuc, France
| | - Sandrine Tournier
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service de Gériatrie, Hôpital Saint Joseph, 26 Boulevard Louvain, 13285, Marseille cedex 08, France
| | - Chantal Butaud
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Unité Mobile de Gériatrie, Hôpital Saint Musse, CH Intercommunal Toulon-La Seyne sur Mer (CHITS), 54 Rue Henri Claire Deville, 83000, Toulon, France
| | - Pierre Guillet
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Unité Mobile de Gériatrie, Hôpital Saint Musse, CH Intercommunal Toulon-La Seyne sur Mer (CHITS), 54 Rue Henri Claire Deville, 83000, Toulon, France
| | - Sophie Nahon
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service d'Hémato-Oncologie, CH du Pays d'Aix, Avenue les Tamaris, 13616, Aix-en-Provence, France
| | - Laure Poudens
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service d'Hémato-Oncologie, CH du Pays d'Aix, Avenue les Tamaris, 13616, Aix-en-Provence, France
| | - Sylvie Kirscher
- Unit of Coordination in Onco-Geriatry (UCOG), PACA-west, Marseille, France.,Service d'Oncologie Médicale, Institut Sainte Catherine (ISC), 250 Chemin de Baigne Pieds, 84918, Avignon cedex 09, France
| | - Sandrine Loubière
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille cedex 05, France
| | - Nadine Diaz
- Service Social, Hôpital Sainte Marguerite, Assistance Publique des Hôpitaux de Marseille (AP-HM), 270 Boulevard de Sainte Marguerite Dromel, 13274, Marseille cedex 09, France
| | - Jean Dhorne
- Direction de la Recherche Clinique et de l'Innovation (DRCI), Assistance Publique des Hôpitaux de Marseille (AP-HM), 80 Rue Brochier, 13354, Marseille Cedex 05, France
| | - Pascal Auquier
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille cedex 05, France
| | - Karine Baumstarck
- EA3279, Self-perceived Health Assessment Research Unit, Aix-Marseille University, 27 Boulevard Jean Moulin, 13385, Marseille cedex 05, France
| |
Collapse
|
16
|
Nahon S, Rastkhah M, Ben Abdelghani M, Soumoudronga RF, Gasnereau I, Labourey JL. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study. Support Care Cancer 2016; 24:1991-1998. [PMID: 26507190 PMCID: PMC4805722 DOI: 10.1007/s00520-015-2986-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Accepted: 10/09/2015] [Indexed: 10/25/2022]
Abstract
PURPOSE Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio(®)-biosimilar of Neupogen(®) (G-CSF; filgrastim)-in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients. METHODS We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy. RESULTS One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio(®) were pain, in particular bone pain. No serious adverse event related to Zarzio(®) was reported. CONCLUSION The results obtained in real-life conditions confirm that Zarzio(®) is efficient and well tolerated in cancer patients.
Collapse
Affiliation(s)
- Sophie Nahon
- Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France
| | | | | | | | - Isabelle Gasnereau
- Sandoz Biopharmaceuticals, 49, Avenue Georges Pompidou, 92593, Levallois-Perret, Cedex, France.
| | | |
Collapse
|
17
|
Metges JP, Crumbach JP, Petran D, Boulanger V, Stamerra O, Desramé J, Nahon S, Aubron-Olivier C, Fernet D, Boschetti G. Management of chemotherapy‐induced anemia (CIA) with biosimilar epoetin alfa (Binocrit) in patients with colorectal cancer (CC): An interim analysis of an ongoing French national observational study (The OncoBOS study). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.3_suppl.742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
742 Background: OncoBOS is a prospective, non-interventional study describing Binocrit use in routine practice in France in patients receiving chemotherapy treatment (CT) for solid tumors, lymphoma, or myeloma. This interim sub-analysis focuses on patients with CC, receiving usual chemotherapeutic agents. Methods: Patients ≥18 years with CC, CIA, and eligible for treatment with Binocrit were included in this analysis. Patients characteristics, data on CIA and its management, and predominant factors considered by the physician in prescribing Binocrit were recorded at baseline (BL), 3-4 weeks and 12 (±1) weeks later. Hemoglobin (Hb) outcomes assessed included the proportion of patients achieving a Hb increase ≥1 and ≥2 g/dL, and the mean Hb change from BL. Results: 96 patients with CC (51 males [53.1%], mean age 68.5 years) from 28 sites were recruited from September 2011 to April 2014. Mean and median BL Hb levels were 9.9 g/dL and 10 g/dL, respectively. The mean increase in Hb level was 1.2 g/dL after 1 month and 1.7 g/dL after 3 months (p<0.001 vs. BL) of Binocrit treatment. A Hb increase ≥1 g/dL was achieved by 56.8% of patients at week 3-4 and 77.6% at week 12; a Hb increase ≥2 g/dL was achieved by 17.9% and 47.4% of patients at the same time points. Patients received a median dose of 30,000 IU Binocrit once weekly. Four of the 96 patients (4.2%) required a dose increase. Transfusion rates remained low at 2.1% and 1.1% at week 3-4 and week 12, respectively. Oral and intravenous (IV) iron supplementation rates were low: oral iron was received by 4.2% and 4.7% of patients at week 3-4 and week 12, respectively; 15.6% and 9.3% of patients received IV supplementation at the same time points. Physicians considered quality of life (49%), fatigue (24%), and avoidance of blood transfusion (15.6%) as predominant factors in the rationale for CIA management. Over the treatment period, no treatment-related adverse reaction was recorded. Conclusions: This sub-analysis indicates that Binocrit, used in routine practice, is effective and well tolerated for the treatment of CIA in patients with CC, whatever CT received.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Sophie Nahon
- Centre Hospitalier d'Aix en Provence, Aix en Provence, France
| | | | | | | |
Collapse
|
18
|
Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe LM, Labourey JL, Lepille D, Maloisel F, Mouysset JL, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H. Erratum to: BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. BMC Cancer 2014. [PMCID: PMC4464620 DOI: 10.1186/1471-2407-14-720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
19
|
Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe LM, Labourey JL, Lepille D, Maloisel F, Mouysset JL, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. BMC Cancer 2014; 14:503. [PMID: 25011615 PMCID: PMC4227033 DOI: 10.1186/1471-2407-14-503] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2014] [Accepted: 07/01/2014] [Indexed: 12/27/2022] Open
Abstract
Background The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation and stringent regulatory procedures, including post-marketing studies. The ORHEO (place of biOsimilaRs in the therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology) study was an observational, longitudinal, multicentre study performed in France to evaluate the efficacy and safety of biosimilar epoetins for the treatment of chemotherapy-induced anaemia (CIA) in the clinical setting. Methods Patients >18 years with CIA (haemoglobin [Hb] <11 g/dL) in association with solid tumours, lymphoma or myeloma and eligible for treatment with an epoetin biosimilar were included in this study. Patient characteristics were recorded at baseline along with anaemia-related information, such as observed and target Hb (as chosen by the treating clinician), brand and dose of epoetin biosimilar prescribed, and details of any other treatments. Patients were then followed-up at 3 and 6 months. The primary endpoint was Hb response (defined as Hb reaching ≥10 g/dL, an increase of Hb ≥1 g/dL since inclusion visit or reaching physician-defined target Hb, with no blood transfusions in the 3 weeks prior to measurement). Other endpoints included adverse events, achievement of target Hb and associated treatments. Results Overall, 2333 patients >18 years (mean age 66.5 years) with CIA (haemoglobin [Hb] <11 g/dL) in association with solid tumours, lymphoma or myeloma and eligible for biosimilar epoetin treatment were included. 99.9% of patients received epoetin zeta (median dose 30,000 IU/week). Mean baseline Hb was 9.61 g/dL, with 35.6% of patients having moderate anaemia (Hb 8–9.5 g/dL). Hb response was achieved in 81.6% and 86.5% of patients at 3 and 6 months, respectively. Overall mean change in Hb level was 1.52 ± 1.61 and 1.72 ± 1.61 g/dL at 3 and 6 months, respectively. Transfusion and thromboembolic event rates were 9.4% and 2.4% at 3 months, and 5.8% and 1.5% at 6 months, respectively. Conclusions Epoetin zeta was effective and well tolerated in the management of CIA in patients with solid tumours, lymphoma and myeloma. Trial registration Trial registration number: NCT02140736 (date of registration: 14 May 2014).
Collapse
Affiliation(s)
- Mauricette Michallet
- Service d'Hématologie, Pavillon Marcel Bérard 1G, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, Lyon- Pierre Bénite 69495, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Ingen-Housz-Oro S, Grootenboer-Mignot S, Ortonne N, Nahon S, Horvath J, Bernardeschi C, Laffitte E, André C, Chollet-Martin S, Wolkenstein P, Chosidow O. Epidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by D-penicillamine in Wilson disease. Br J Dermatol 2014; 171:1574-6. [PMID: 24888462 DOI: 10.1111/bjd.13153] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Retornaz F, Guillem O, Gholam D, Codoul JF, Bratisevic C, Morvan F, Rinaldi Y, Barriere N, Nahon S, Butaud C, Guerin O, Boulahssass R, Rousseau F. Frailty markers for prediction of mortality in first-line chemotherapy for colon cancer patients: Results of MOST/ASRO 101 study. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9553] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Dany Gholam
- Centre Hospitalier de la Dracenie, Draguignan, France
| | | | | | | | | | | | - Sophie Nahon
- Centre Hospitalier d'Aix en Provence, Aix en Provence, France
| | | | | | | | | |
Collapse
|
22
|
Oro S, Grootenboer-Mignot S, Ortonne N, Nahon S, Horvath J, Bernardeschi C, Laffitte E, André C, Wolkenstein P, Chosidow O. La D-pénicillamine pourrait induire une autoimmunité anti-collagène VII. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
23
|
Charpignon C, Lesgourgues B, Pariente A, Nahon S, Pelaquier A, Gatineau-Sailliant G, Roucayrol AM, Courillon-Mallet A. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment Pharmacol Ther 2013; 38:946-54. [PMID: 23981105 DOI: 10.1111/apt.12465] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Revised: 04/13/2013] [Accepted: 08/04/2013] [Indexed: 12/26/2022]
Abstract
BACKGROUND The proportion (and even the reality) of peptic ulcer disease (PUD) not related to H. pylori or NSAID/aspirin is debated. AIM To analyse the current epidemiological and clinical characteristics of peptic ulcer disease in French general hospitals. METHODS Prospective multicentre study of patients with peptic ulcer disease in 32 French general hospitals over 1 year. H. pylori status was assessed by histology, and/or serology and/or C13-urea breath test. NSAID/aspirin intake (obtained by direct interview) and data about concomitant diseases were collected on the day of endoscopy. RESULTS Nine hundred and thirty-three patients were selected during the year 2009. After exclusion of 118 patients with only erosive duodenitis, 24 with major missing data, 13 with other causes of ulcer and 65 negative for H. pylori by only one test, 713 patients were classified into four groups: 285 (40.0%) had only H. pylori infection; 133 (18.7%) only gastrotoxic drugs; 141 (19.8%) had both and 154 (21.6%) neither H. pylori infection nor gastrotoxic drug intake ('idiopathic ulcers'). Patients with idiopathic ulcers differed in many ways both from H. pylori and NSAID/aspirin groups. However, multivariate analysis identified only three independent predictors: age, French metropolitan origin and the presence of comorbidities. CONCLUSION In a general hospital-based population in France, peptic ulcer disease appears idiopathic in a fifth of cases.
Collapse
Affiliation(s)
- C Charpignon
- Department of Gastroenterology, Villeneuve St Georges Hospital, Villeneuve St Georges, France
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Pariente A, Nahon S. Letter: Peptic ulcer bleeding and liver cirrhosis--different diseases and different prognosis, too? Aliment Pharmacol Ther 2013; 37:368-9. [PMID: 23281728 DOI: 10.1111/apt.12155] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2012] [Accepted: 10/31/2012] [Indexed: 12/25/2022]
|
25
|
Nahon S, Hagège H, Latrive JP, Rosa I, Nalet B, Bour B, Faroux R, Gower P, Arpurt JP, Denis J, Henrion J, Rémy AJ, Pariente A. Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. Endoscopy 2012; 44:998-1008. [PMID: 23108771 DOI: 10.1055/s-0032-1310006] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND AND STUDY AIMS The mortality rate from upper gastrointestinal bleeding (UGIB) remains high, at 5 % - 10 %. The aim of the current study was to describe the epidemiological characteristics, prognostic factors, and actual practice in a cohort of patients with UGIB admitted to French general hospitals. METHODS From March 2005 to February 2006, a prospective multicenter study was conducted at 53 French hospitals. A total of 3298 patients admitted for UGIB were enrolled consecutively. Patient data were collected up to the date of discharge from hospital. RESULTS Data were available for 2130 men and 1073 women (mean age 63 ± 18 years), one-third of whom were taking drugs that would increase the risk of UGIB. The two main causes of bleeding were peptic ulcers (38 %) and esophagogastric varices (EGV) or portal hypertensive gastropathy (24.5 %). Mean Rockall score was 5.0 ± 2.3. Endoscopy was performed on 96 % of patients (within 24 hours in 79 %), and 66 % of those with ulcers and 62.5 % of the EGV patients underwent hemostatic therapy when indicated. Rebleeding occurred in 9.9 % of the patients, and 8.3 % died. Independent predictors of rebleeding were: need for transfusion (odds ratio [OR] 19.1; 95 % confidence interval [95 %CI] 10.1 - 35.9); hemoglobin < 10 g/dL (OR: 1.7; 95 %CI 1.1 - 3.3); Rockall score (OR: 1.4 for each 1 point score increase; 95 %CI 1.0 - 1.9), systolic blood pressure < 100 mmHg (OR: 1.9; 95 %CI 1.4 - 2.5), and signs of recent bleeding (OR: 2.4; 95 %CI 1.7 - 3.5). Independent predictors of mortality were: Rockall score (OR: 2.8; 95 %CI 2.0 - 4.0), co-morbidities (OR: 3.6 for each additional co-morbidity; 95 %CI 2.0 - 6.3), and systolic blood pressure < 100 mmHg (OR: 2.1; 95 %CI 1.8 - 2.8). Rockall score, blood pressure and co-morbidities were taken as continuous variables meaning that the OR was 1.4 for every point increase, it was the same for blood pressure. CONCLUSION UGIB still occurs mainly as a result of peptic ulcers and portal hypertension in France, and causes significant rates of mortality. There is scope for improvement via better prevention (better use of UGIB-facilitating drugs), endoscopic therapy, and management of co-morbidities.
Collapse
Affiliation(s)
- S Nahon
- Service d'hepatogastroenterologie, Centre Hospitalier Montfermeil, Montfermeil, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Trompette ML, Nahon S, Tuszynski T, Poupardin C, Jouannaud V, Lesgourgues B. [Treatment of a gastric telangiectasia with endoscopic band ligation]. Gastroenterol Clin Biol 2009; 33:1070-2. [PMID: 19864097 DOI: 10.1016/j.gcb.2009.08.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2009] [Revised: 08/05/2009] [Accepted: 08/07/2009] [Indexed: 11/30/2022]
|
27
|
Lotz J, Husseini F, Finck M, Rotarski M, Bastit L, Riviere A, Youssef A, Mouysset J, Nahon S, Piolat V. French experience of patient management when receiving oral vinorelbine chemotherapy (NVBO) for metastatic breast cancer: Final results of a prospective observational survey on practices. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e12013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12013 Background: An observatory on practices has been implemented in France with the aim of investigating the correlation between patient (pt) profile and the use of an oral chemotherapy (OCT), NVBO. Methods and Materials: Three questionnaires were used: a “Physician” questionnaire (medical practice conditions, role of OCT), a “Patient” questionnaire (pt disease history, prescription selection factors and compliance), and a Patient Preference self-questionnaire (partly based on the EORTC QLQ-BR23). Results: Between February 06 and February 08,355 pts were enrolled in 47 centers. Breast tumours were classified as having limited aggressiveness with or without visceral metastasis (41.2%) or slowly progressing visceral metastasis and DFI>24 months (42.3%) or aggressive disease with visceral metastasis and DFI<12 months (16.5%). Pts had previously received hormonotherapy in 72.4%, iv CT in 78.6% and OCT in 31%. NVBO was prescribed as monotherapy in 53,6% and association in 46,4%, with iv in 35% (66.7% with trastuzumab), with oral in 65% ( 97.2% with capecitabine ). 86.2% of pts preferred OCT for 3 main reasons : more time with their family, social life maintained and treatment at home. Physicians’ major parameters of OCT choice according to score (1 to 4) were : patient-related factors (QOL 3.61), reduced hospital stays (2.99) and problems related to venous administration (2.62). Conclusion: NVBO brings added value in terms of pt convenience allowing improved QOL and reduced hospital stays while keeping optimal compliance to treatment schedule. [Table: see text]
Collapse
Affiliation(s)
- J. Lotz
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - F. Husseini
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - M. Finck
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - M. Rotarski
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - L. Bastit
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - A. Riviere
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - A. Youssef
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - J. Mouysset
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - S. Nahon
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| | - V. Piolat
- Tenon Hospital, Paris, France; Louis Pasteur Hospital, Colmar, France; Clinique du Parc, Croix, France; Clinique Paulmy, Bayonne, France; Centre Frédéric Joliot, Rouen, France; Francois Baclesse Cancer Centre, Caen, France; Jean Godinot Cancer Centre, Reims, France; Centre Medical Aix en Provence, Aix en Provence, France; Centre Hospitalier d’Aix en Provence, Aix en Provence, France; Institut de Recherche Pierre Fabre, Boulogne, France
| |
Collapse
|
28
|
Nahon S, Cadranel JF, Chazouilleres O, Biour M, Jouannaud V, Marteau P. Liver and inflammatory bowel disease. ACTA ACUST UNITED AC 2009; 33:370-81. [DOI: 10.1016/j.gcb.2009.02.037] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2008] [Revised: 12/22/2008] [Accepted: 02/16/2009] [Indexed: 02/07/2023]
|
29
|
Nahon S, Patey-Mariaud De Serre N, Lejeune O, Huchet FX, Lahmek P, Lesgourgues B, Traissac L, Bodiguel V, Adotti F, Tuszynski T, Delas N. Duodenal intraepithelial lymphocytosis during Helicobacter pylori infection is reduced by antibiotic treatment. Histopathology 2006; 48:417-23. [PMID: 16487363 DOI: 10.1111/j.1365-2559.2006.02358.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
AIM To evaluate clinical, biological and immunological features of patients with increased duodenal intraepithelial lymphocytes (IELs), and its relation to Helicobacter pylori (HP) and coeliac disease (CD). METHODS We have studied all patients accrued over a 4-year period with increased duodenal IELs. Those patients were recalled for biological and immunological evaluation and a second endoscopy. RESULTS Twenty-three from a total of 639 patients were identified and 17 of them were included in the study. The median duodenal IEL count was 59 per 100 epithelial cells. Twelve (71%) patients were HP+; eight of them received HP eradication. At the second endoscopy the duodenal IEL count was significantly lower 2 months after HP eradication (73 versus 28), while the IEL count was unchanged in those patients seronegative for HP (n = 5) or those in whom it was not eradicated (n = 4) (55 versus 55). No patient had coeliac antibodies, four expressed HLA-DQ2, lower than in the general population, and the prevalence of CD was 2% (12/639 patients). CONCLUSION In some cases an increased duodenal IEL count may be due to an inappropriate host response to HP. HP screening and eradication should be considered before recommending a gluten-free diet.
Collapse
Affiliation(s)
- S Nahon
- Service d'Anatomopathologie, Centre Hospitalier Intercommunal, Le Raincy-Montfermeil, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Nallet O, Nahon S, Cormier B, Cadoux L, Iung B, Mazouz S, Vitaux F, Richemond J, Couetil JP, Sergent J. [Isolated carcinoid tumor of the ovary disclosed by tricuspid insufficiency]. Arch Mal Coeur Vaiss 2003; 96:144-8. [PMID: 14626739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
A 68-year old woman was hospitalised because of isolated right heart failure. Doppler echocardiography revealed severe tricuspid regurgitation with thickened, shortened, hypomobile leaflets. Pulmonary valve was thickened with mild pulmonary regurgitation. Mitral and aortic valves were normal. The patient was finally diagnosed with carcinoid heart disease from an isolated ovarian carcinoid cancer without hepatic metastases. Ovarectomy was performed and the patient was considered cured of her cancer. Because of refractory right heart failure, she underwent tricuspid valve replacement with a bioprosthesis. Such cardiovascular manifestations are rarely the presenting symptoms of carcinoid disease. Carcinoid heart disease from ovarian primary cancer is exceptional. In this circumstance, carcinoid cardiac lesions may develop in the absence of hepatic metastases because the venous blood from the ovaries drains into the inferior vena cava without hepatic first past effect. Surgical resection of primary ovarian carcinoid tumor is often curative and the prognosis depends mainly on the cardiac condition. The diagnosis of carcinoid syndrome should be discussed in patients with organic tricuspid regurgitation without left valvular disease.
Collapse
Affiliation(s)
- O Nallet
- Fédération de cardiologie, centre hospitalier, rue du Général-Leclerc 93370 Le Raincy-Montfermeil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Chauvet B, Villers A, Davin JL, Nahon S. [Update on screening, diagnosis and treatment of cancer of the prostate]. Bull Cancer 2002; 89:37-45. [PMID: 11847025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Recent progress in management of prostate cancer concern screening and treatment. The use of PSA and rectal examination advances the diagnosis by 5 to 10 years and shift the stage at the time of diagnosis toward curative localized intraprostatic disease. The impact of systematic screening remains controversial. However, individual screening explains, at least in part, the decrease of specific mortality due to prostatic cancer, recently observed in USA. PSA and lymphadenectomy have also contributed to a better selection of patients referred for local treatment by prostatectomy or radiotherapy. Radical prostatectomy is recommended for patients before 70 with T2 or less, Gleason score less than 8 and PSA less than 15 ng/ml. With that selection, disease-free survival reaches 75 to 80% at 10 years. Recently, dramatic improvement in radiotherapy techniques have been achieved, leading to a better local control by increasing the dose over 70 Gy without additional toxicity. Brachytherapy is also widely used for good prognosis localized disease. Limitant acute urinary side effects have been reported and results seem similar to those reported after prostatectomy or conformal radiotherapy. Recent randomized trials have demonstrated a benefit of early hormonal therapy concurrent with radiotherapy for patients with poor prognosis localized disease. For hormonoresistant metastatic disease, chemotherapy has been used with limited palliative benefit. New drugs are currently evaluated.
Collapse
Affiliation(s)
- Bruno Chauvet
- Institut Sainte-Catherine, BP 846, 84082 Avignon Cedex. 2
| | | | | | | |
Collapse
|
32
|
Nahon S, Brewer Y, Kirscher S, Chauvet B, Berger C, Serin D. [Axillary lymph node and bone marrow micrometastases of breast cancer]. Bull Cancer 2001; 88:1095-104. [PMID: 11741804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Micrometastatic disease from breast cancer is a major concern both for clinicians and pathologists. Histologically, they can be defined as potentially invasive microfoci of tumoral cancer cells located in the vicinity of blood vessels and are a distinct entity from residual disease. They are mainly looked for in bone marrow and lymph nodes specimens and their diagnosis is currently easier thanks to immunohistochemistry. Provided a standard definition of micrometastatic disease and standard screening procedures can be met, the presence of micrometastases at the time of diagnosis could represent a major parameter in therapeutic decision-making. Although controversial, the presence of medullary and axillary lymph node micrometastases appears to be a major prognostic factor in terms of survival. Recognition of this entity could help in better defining the high-risk subset of patients who would potentially benefit from adjuvant chemotherapy.
Collapse
Affiliation(s)
- S Nahon
- Institut Sainte-Catherine, chemin du Lavarin, 84000 Avignon.
| | | | | | | | | | | |
Collapse
|
33
|
Nahon S, Pisanté L, Delas N. A successful switch from prednisone to budesonide for neuropsychiatric adverse effects in a patient with ileal Crohn's disease. Am J Gastroenterol 2001; 96:1953-4. [PMID: 11419871 DOI: 10.1111/j.1572-0241.2001.03917.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
34
|
Diaz E, Nahon S, Charachon A, Traissac L, Lenoble M, Challier E, Delas N. [Portal vein thrombosis associated with a myeloproliferative disorder, prothrombin G20210A mutation, antiphospholipid syndrome, with repermeation during anticoagulant therapy]. Gastroenterol Clin Biol 2001; 25:549-51. [PMID: 11521110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Portal vein thrombosis, except in hepatocellular carcinoma and severe cirrhosis, is due to one or several prothrombotic disorders with or without a local precipitating factor. We report a case of a portal and splenic vein thrombosis, without cavernoma and varices which occurred in a 72-year-old man with abdominal pain and weakness. Three prothrombotic states including latent myeloproliferative disorder, antiphospholipid syndrome, and factor II G202101 mutation, were observed. Anticoagulant treatment resulted in complete repermeation of the portal and splenic veins without a hemorrhagic event. This illustrates that several prothrombotic states may occur in a single patient with portal vein thrombosis. Early anticoagulant therapy, in recent portal vein thrombosis, can result in repermeation.
Collapse
Affiliation(s)
- E Diaz
- Service d'Hépato-Gastroentérologie, Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France
| | | | | | | | | | | | | |
Collapse
|
35
|
Nahon S, Boudet MJ, Godeberge P, Mal F, Lévy P, Perniceni T, Gayet B. [Achalasia mimicking psychiatric eating disorders]. Gastroenterol Clin Biol 2001; 25:313-5. [PMID: 11395678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Anorexia nervosa and psychogen vomiting are psychiatric eating disorders characterized by unexplained weight loss and induced vomiting. These diagnoses require absence of somatic disease. Achalasia is a primary disorder of the esophagus that can be responsible for the same symptoms. This may occult the real diagnosis, especially as dysphagia is not constant and variable in time. We report four cases of achalasia mistakenly diagnosed and treated as anorexia nervosa or psychogen vomiting. Achalasia was unrecognized because specific symptoms, such as dysphagia, were overlooked or misinterpreted by the patients' physicians and psychiatrists, or by the patients themselves. In patients with such eating disorders considered to be psychiatric, physicians should inquire about signs suggestive of achalasia. The diagnosis of achalasia is suspected by imaging and endoscopy, and confirmed or ruled out by manometry.
Collapse
Affiliation(s)
- S Nahon
- Département Médico-Chirurgical de Pathologie Digestive, Institut Montsouris, et Université Paris-VI, Paris
| | | | | | | | | | | | | |
Collapse
|
36
|
Nahon S, Dugue C, Adotti F, Manet S, Bouzard D, Tuszinski T, Lesgourgues B, Delas N. [Small bowel obstruction secondary to ischemic stenosis due to cholesterol crystal embolism]. Ann Med Interne (Paris) 2000; 151:417-20. [PMID: 11033479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Cholesterol crystal embolization is a well-known disorder resulting from release of cholesterol crystals from ulcerous atherosclerotic plaques. Gastrointestinal involvement occurs in about a third of cases, but it is usually asymptomatic. We report a case of an old woman with small bowel obstruction secondary to atheromatous embolism. She was treated by acenocoumarol for atrial fibrillation and pulmonary embolism. Two weeks before admission for small bowel obstruction, she had a watery diarrhea. After 3 weeks of parenteral nutrition, she underwent resection of the involved ileum. Pathological examination showed a small bowel stricture secondary to atheromatous embolism. Cholesterol emboli should be considered as a potential cause of small bowel obstruction in old patient who has taken anticoagulant therapy or after vascular invasive procedure.
Collapse
Affiliation(s)
- S Nahon
- Service d'Hépato-Gastroentérologie, Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Seksik P, Nahon S, Lesgourgues B, Cadranel JF, Mariaud De Serre N, Lenoble M, Lahmeck P, Charoud A, Delas N. [Efficacity of treatment with lamivudine in two patients with severe reactivation of hepatitis B after withdrawal of chemotherapy]. Gastroenterol Clin Biol 2000; 24:671-4. [PMID: 10962392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Reactivation of chronic infection is a serious complication during and especially after the withdrawal of cancer chemotherapy in hepatitis B virus carriers. Mortality is high, ranging from 4 to 20%. We report two cases of severe reactivation, after withdrawal of chemotherapy for chronic lymphocytic leukemia in one case and for a bladder tumor in the other. Recovery occurred with lamivudine therapy. Morbidity and mortality are common in these cases, especially when intensive chemotherapy and/or chronic hepatitis and/or precore mutants viruses are involved. Although lamivudine seems to be effective in these cases, prophylactic use has not been clearly defined and must be evaluated.
Collapse
Affiliation(s)
- P Seksik
- Service d'Hépato-gastroentérologie et de Médecine Interne, Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lapidot M, Goldray O, Ben-Joseph R, Cohen S, Friedmann M, Shlomo A, Nahon S, Chen L, Pilowsky M. Breeding tomatoes for resistance to tomato yellow leaf curl begomovirus. ACTA ACUST UNITED AC 2000. [DOI: 10.1111/j.1365-2338.2000.tb00902.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Nahon S, Bouhnik Y. [Investigation of iron deficiency]. Gastroenterol Clin Biol 2000; 24:B62-7. [PMID: 10891766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
- S Nahon
- Service d'Hépato-Gastroentérologie et Assistance Nutritive, Hôpital Lariboisière-Saint-Lazare, 2, rue Ambroise-Paré, 75475 Paris Cedex 10
| | | |
Collapse
|
40
|
Bouhnik Y, Nahon S, Landi B. [Synopsis: diagnosis and treatment of occult digestive tract bleeding]. Gastroenterol Clin Biol 2000; 24:317-23; quiz 316, 333. [PMID: 10804338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Affiliation(s)
- Y Bouhnik
- Service d'Hépato-Gastroentérologie et Assistance Nutritive, Hôpital Lariboisière Saint-Lazare, 2, rue Ambroise-Paré, 75475 Paris Cedex 10
| | | | | |
Collapse
|
41
|
Nahon S, Hoang JM, Tuszynski T, Mariaud De Serre N, Lesgourgues B, Delas N. [Hemangioma of the small bowel manifesting as gastrointestinal bleeding, diagnosed by pushed enteroscopy]. Gastroenterol Clin Biol 1999; 23:1406-7. [PMID: 10642633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|
42
|
Rosa I, Nahon S, Cohen C, Abd Alsamad I, Fléjou JF, Hagege H, Chousterman M. [Ticlopidine-induced lymphocytic colitis]. Ann Med Interne (Paris) 1999; 150:437-9. [PMID: 10544755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Lymphocytic colitis is a clinico-pathological syndrome characterized by chronic diarrhea, normal endoscopy, diffuse colonic mucosal inflammatory changes. Collagenous colitis is defined by a thickening of the collagen plate. The etiology is unknown but immune disorders have been frequently associated with it and it has been linked with the taking of certain drugs such as nonsteroïd anti-inflammatory drugs or veinotonics. We are reporting a case of microscopic colitis associating both lymphocytic and collagenous colitis, wich induced chronic diarrhea in a 65-year-old man. It appeared after he had taken ticlopidine. Diarrhea stopped after he had discontinuated ticlopidine, and recurred after he resumed taking the drug. Histological damages from lymphocytic colitis improved six month after he had stopped taking ticlopidine. Chronic diarrhea induced by ticlopidine might be caused by lymphocytic colitis.
Collapse
Affiliation(s)
- I Rosa
- Service d'Hépato-Gastroentérologie, Centre Hospitalier Intercommunal de Créteil
| | | | | | | | | | | | | |
Collapse
|
43
|
Nahon S, Marteau P, Matuchansky C. [Crohn's disease and blood vessels]. Gastroenterol Clin Biol 1998; 22:175-87. [PMID: 9762192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
- S Nahon
- Service de Gastroentérologie et d'Assistance Nutritive, Hôpital Saint-Lazare, Paris
| | | | | |
Collapse
|
44
|
Le Chevalier T, Monnier A, Aapro M, Douillard J, Nahon S, Sun X, De pas T, Loret C, Bougon N, Bérille J. Interim report of a phase i study of docetaxel (Taxotere®) in combination with vinorelbine in chemotherapy naive patients with metastatic or inoperable non small cell lung cancer (NSCLC). Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)85844-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Douillard J, Monnier A, Le Chevalier T, Aapro M, Nahon S, Sun X, De Pas T, Loret C, Anneheim-Herbelin S, Bougon N, Bérille J. 223 Docetaxel in combination with vinorelbine in chemotherapy naive patients with metastatic or unresectable non-small cell lung cancer (NSCLC): Preliminary results of a phase I study. Lung Cancer 1997. [DOI: 10.1016/s0169-5002(97)89605-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Brochériou I, Nahon S, Coffin B, Mégraud F, Matuchansky C, Rambaud JC, Lavergne A. [Association of a low-grade MALT lymphoma and a slightly differentiated adenocarcinoma of the stomach]. Ann Pathol 1997; 17:109-12. [PMID: 9220999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The development of synchronous gastric adenocarcinoma and primary gastric lymphoma is rare. We report a case of low grade B-cell lymphoma of mucosa associated lymphoid tissue intermingled with a gastric adenocarcinoma and without Helicobacter pylori infection. This observation leads to discuss the pathogenesis of these tumors and the role of Helicobacter pylori infection in the development of gastric lymphoma and carcinoma.
Collapse
Affiliation(s)
- I Brochériou
- Service d'Anatomie et de Cytologie Pathologiques, Hôpital Lariboisière, Paris
| | | | | | | | | | | | | |
Collapse
|
47
|
Benallegue A, Dubois M, Benabdallah S, Nahon S, Grangaud JP. [Apropos of 12 cases of duodenal ulcer in Algerian children]. Tunis Med 1968; 46:163-79. [PMID: 5674541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
48
|
Benallegue A, Dubois M, Benabdallah S, Nahon S, Grangaud JP, Colonna P, Belkhodja A, Zidane C, Hamladji RM, Messerschmitt J. [Anemia in the course of rickets (apropos of 50 cases)]. Tunis Med 1967; 45:93-105. [PMID: 5595433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
49
|
Benallegue A, Dubois M, Benabdallah S, Nahon S, Grangaud JP. [Panorama of chronic anemias in children observed in the pediatric clinic of Parnet Hospital, Algeria]. Tunis Med 1967; 45:107-17. [PMID: 5595429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|